LifeMD (LFMD) awards 337,500 restricted stock units to CFO Kavthekar

Q: How many LifeMD (LFMD) shares were granted to the CFO?

The CFO, Atul Kavthekar, was granted 337,500 shares of LifeMD Common Stock in the form of restricted stock units. After this grant, his direct ownership reported in the filing is also 337,500 shares .

Q: What is the vesting schedule for the CFO’s LifeMD (LFMD) RSU grant?

The 337,500 RSUs vest in three installments: 112,500 on March 16, 2027 , 112,500 on March 16, 2028 , and the remaining shares on March 16, 2029 , subject to continued service conditions.

Q: Is the LifeMD (LFMD) CFO’s Form 4 transaction a market buy or sell?

No, the Form 4 reports an equity grant , not a market trade. The CFO acquired 337,500 restricted stock units at a stated price of $0.00 as part of his compensation package.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Kavthekar Atul reported acquisition or exercise transactions in this Form 4 filing.

LifeMD, Inc. reported that its Chief Financial Officer, Atul Kavthekar, received a grant of 337,500 shares of Common Stock in the form of restricted stock units. The award was recorded at a price of $0.00 per share, reflecting a compensation grant rather than a market purchase.

Following this grant, Kavthekar directly holds 337,500 shares. The units vest over time: 112,500 shares on March 16, 2027, another 112,500 shares on March 16, 2028, and the remaining portion on March 16, 2029, aligning his compensation with multi‑year service.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Kavthekar Atul

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	337,500	$0.00	--

Holdings After Transaction: Common Stock — 337,500 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

RSUs granted: 337,500 shares Grant price: $0.00 per share Shares held after grant: 337,500 shares +3 more

6 metrics

RSUs granted 337,500 shares Restricted stock unit grant to CFO on May 11, 2026

Grant price $0.00 per share Stated price for RSU compensation grant

Shares held after grant 337,500 shares Direct ownership reported following transaction

First vesting tranche 112,500 shares Vest on March 16, 2027

Second vesting tranche 112,500 shares Vest on March 16, 2028

Final vesting tranche 112,500 shares Remaining RSUs vest on March 16, 2029

Key Terms

restricted stock units, Chief Financial Officer, Form 4

3 terms

restricted stock units financial

"Grant of restricted stock units which vest 112,500 on March 16, 2027"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Chief Financial Officer financial

"officer_title": "Chief Financial Officer""

A Chief Financial Officer (CFO) is the person in charge of a company's money and financial planning. They decide how to spend, save, and invest funds to help the company grow and stay stable. Their role is important because good financial decisions keep the company healthy and successful.

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Form 4 Insider Transactions: What Each Field Means →

05/13/2026 - 05:12 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kavthekar Atul

(Last)

(First)

(Middle)

C/O LIFEMD

236 FIFTH AVENUE, SUITE 400

(Street)

NEW YORK

10001

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
LifeMD, Inc. [ LFMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/11/2026		A		337,500	A	$0.00⁽¹⁾	337,500	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Grant of restricted stock units which vest 112,500 on March 16, 2027, 112,500 on March 16, 2028 and the remainder on March 16, 2029.

	/s/ Atul Kavthekar	05/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did LifeMD (LFMD) disclose in this Form 4 filing?

LifeMD disclosed that its Chief Financial Officer, Atul Kavthekar, received a grant of 337,500 restricted stock units of Common Stock. This is a compensation-related equity award, not an open-market share purchase or sale.

How many LifeMD (LFMD) shares were granted to the CFO?

The CFO, Atul Kavthekar, was granted 337,500 shares of LifeMD Common Stock in the form of restricted stock units. After this grant, his direct ownership reported in the filing is also 337,500 shares.

At what price were the LifeMD (LFMD) RSUs granted to the CFO?

The restricted stock units granted to the CFO carry a stated price of $0.00 per share. This indicates a compensation grant from the company rather than a purchase in the open market.

What is the vesting schedule for the CFO’s LifeMD (LFMD) RSU grant?

The 337,500 RSUs vest in three installments: 112,500 on March 16, 2027, 112,500 on March 16, 2028, and the remaining shares on March 16, 2029, subject to continued service conditions.

Is the LifeMD (LFMD) CFO’s Form 4 transaction a market buy or sell?

No, the Form 4 reports an equity grant, not a market trade. The CFO acquired 337,500 restricted stock units at a stated price of $0.00 as part of his compensation package.